Bringing the fundamentals into focus…
Back to Assembly Biosciences, Inc.
How Assembly Biosciences, Inc. stacks up
ASMB · against 1,336 other Healthcare companies
Valuation
54/ 100
Above the middle of the pack.
Ranked #609 of 1,337 · scores higher than 54% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 50–59, including ASMB · Click a bar to see the companies
Why valuation scores 54?
Weighted metrics compared with all Healthcare companies.A mix: stronger earnings yield, but weaker EBITDA yield and free cash flow yield than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -9.9% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -9.5% vs peer median 0.0%
- higher earnings for the price paid: stronger than 79% of peers. Earnings yield: 5.2% vs peer median 1.5%
Metric by metric
Position: dot = ASMB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ASMB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 5.2% | 1.5% | 79% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | -9.9% | 4.2% | 17% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | -9.5% | -1.0% | 27% | 20% | |
| Book yieldHigher is better · 1,306 reported | 77.3% | 37.9% | 80% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ASMBScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score